A new meta-analysis looked at resting energy expenditure in women with polyendocrine metabolic ovarian syndrome, also called PMOS, compared with women without the condition. Resting energy expenditure is the number of calories the body burns at rest. The analysis found that the average difference between the two groups was only 31 calories per day. The 95% quantile interval ranged from -44 to 113 calories per day, which includes zero. That means the difference was not statistically clear. The analysis also looked at how much resting energy expenditure varied from person to person. The contrast ratio for between-person standard deviations was 0.98, with a 95% quantile interval of 0.71 to 1.32. This suggests the amount of variation was similar in both groups. The study did not report side effects, funding, or conflicts of interest. It also did not report limitations. The main takeaway is that resting energy expenditure does not appear to differ in a meaningful way between women with and without PMOS. Group-level differences were small, not statistically significant, and not likely to be physiologically important. This does not mean that weight or metabolism concerns in PMOS are not real. It means that, on average, resting calorie burn may not be the main driver. Anyone with questions about their own metabolism or PMOS should talk with their doctor.
Resting energy expenditure does not meaningfully differ between women with and without PMOSPCOS May Not Change Resting Energy Expenditure Much
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This meta-analysis synthesized evidence on resting energy expenditure (REE) in women with and without polyendocrine metabolic ovarian syndrome (PMOS). The scope focused on group-level differences in mean REE and between-person variation in REE. Sample size, setting, and follow-up were not reported.
The pooled mean REE difference was 31 kcal/day (95% quantile interval: -44 to 113 kcal/day). The contrast ratio for between-person standard deviations was 0.98 (95% quantile interval: 0.71 to 1.32). Both estimates are small and the intervals include values consistent with no difference or with differences in either direction.
The authors conclude that REE does not meaningfully differ between women with and without PMOS, and that group-level differences are small, insignificant, or not physiologically relevant. Limitations of the meta-analysis were not reported, and funding or conflicts of interest were not reported. Safety outcomes were not reported.
For practice, these findings suggest that REE should not be assumed to differ systematically in women with PMOS. The evidence does not support using REE as a distinguishing clinical feature, though the certainty of the evidence and the quality of included studies were not reported.
How this fits prior evidence
This meta-analysis addresses a gap in prior coverage by directly comparing resting energy expenditure between women with and without PMOS. Prior items covered microglia as candidate contributors, prepregnancy HOMA-IR quartiles and reproductive outcomes, dry eye symptoms, clomiphene citrate stair-step protocols, and weight-neutral insulin-sensitivity-centered pathways. The current finding that REE does not meaningfully differ contrasts with assumptions that energy expenditure is altered in PMOS, and it aligns with the broader emphasis on metabolic and reproductive outcomes rather than resting energy expenditure as a distinguishing feature.
Common questions
What is resting energy expenditure?
Resting energy expenditure is the number of calories your body burns when you are at rest. It is a major part of how many calories you burn each day. This analysis looked at whether it differs between women with PMOS and women without it.
Did the study find a real difference in calories burned?
The average difference was 31 calories per day. The 95% quantile interval ranged from -44 to 113 calories per day, which includes zero. That means the difference was not statistically clear and is not likely to be physiologically important.
Does this mean PMOS does not affect metabolism?
No. The analysis only looked at resting energy expenditure. It did not measure other parts of metabolism, activity, or weight. The study concludes that resting energy expenditure does not meaningfully differ between women with and without PMOS, but that is just one measure.
Was there a lot of variation between people?
The analysis looked at between-person variation. The contrast ratio for standard deviations was 0.98, with a 95% quantile interval of 0.71 to 1.32. This suggests the amount of variation was similar in both groups.
Should I change anything based on this?
This analysis does not give personal medical advice. If you have PMOS and concerns about your metabolism or weight, talk with your doctor. They can help you understand what is right for you.
More on Polycystic Ovary Syndrome
View Original Abstract ↓
SGLT2 inhibitors improve glycemic control and blood pressure in patients with diabetic chronic kidney disease
SGLT2 inhibitors improve blood sugar and weight in kidney disease
Related in Diabetes & Endocrinology
From Other Specialties
